Monday, October 17, 2005, including Plenary Sessions

OncoLink coverage of the Annual Meeting of the American Society for Therapeutic Radiology And Oncology, ASTRO, October 16-20, 2005, held in Denver, Colorado. OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.

Today's coverage includes Plenary Sessions.

The Big Blue Bear at the Denver Convention Center - 40 foot bear sculpted by Lawrence Argent

Accelerated Partial Breast Irradiation (APBI): An Analysis of Variables Associated with Late Toxicity after HDR Interstitial Brachytherapy Presenter: S. KaufmanPresenter's Affiliation: Radiation Oncology, Tufts/ Brown Universities, Boston, MA, Radiation Oncology, Virginia Commonwealth University, Richmond, VAType of Session: ScientificBackground There is currently limited data...
An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 Presenter: C. A. LawtonPresenter's Affiliation: Medical College of WisconsinType of Session: ScientificBackground There is much interest in both the use and timing of androgen suppression during external beam radiation treatment of intermediate- to...
ASTRO Patient Summary: An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13 Prostate cancer is often treated with radiation and hormone...
ASTRO Patient Summary: Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10 This study looked at patients with early stage (I and II) Hodgkin's disease. There is some controversy over the dose of radiation therapy and the number of cycles of standard chemotherapy (ABVD regimen) these patients should receive. Patients were...
ASTRO Patient Summary: Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer This presentation reviewed a recent study involving postmenopausal women with early stage, hormone receptor positive breast...
ASTRO Patient Summary: Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) This study looked at prostate cancer patients who were found to have "adverse pathologic features" (invasion...
ASTRO Patient Summary: Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial This study examined patients with T3 or T4 rectal adenocarcinoma with no metastases. Patients were assigned to receive...
ASTRO Patient Summary: Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Stage I testicular cancer (seminoma) is managed by first-line surgery (orchiectomy) and then, most commonly, observation without additional therapy. Many centers offer...
Comparison of 30 Gy versus 20 Gy Involved Field Radiotherapy After Two Versus Four Cycles ABVD in Early Stage Hodgkin's Lymphoma: Interim Analysis of the German Hodgkin Study Group Trial HD10 Presenter: R.P. MullerPresenter's Affiliation: Medical University of Vienna, AustriaType of Session: PlenaryBackground Combined modality treatment consisting of few cycles of chemotherapy, usually ABVD, followed by involved field radiotherapy...
Does Pelvis and Prostate Radiation Therapy Compared to Prostate Radiation Therapy Alone Improve Survival in Patients with Non Metastatic Prostate Carcinoma? Preliminary Results of the Prospective Randomized GETUG 01 Trial Presenter: P. PommierPresenter's Affiliation: Centre Leon Berard, Lyon, FranceType of Session: ScientificBackground There has been ongoing controversy regarding the role of whole pelvis radiotherapy in patients with non-metastatic prostate cancer....
Location and Control of Local Disease Predict Overall Survival and Distant Metastases Free Survival in Patients with Ipsilateral Breast Tumor Recurrence after Breast Conserving Therapy for Stage I/II Breast Cancer Presenter: Y. ChenPresenter's Affiliation: Radiation Oncology, Massachusetts General Hospital, Boston, MAType of Session: ScientificBackground The best approach to ipsilateral breast tumor recurrence after breast conserving surgery and...
Lumpectomy Plus Tamoxifen or Arimidex With or Without Whole Breast Irradiation in Women with Favorable Early Breast Cancer Presenter: R. PoetterPresenter's Affiliation: Dept. of Radiotherapy and Radiobiology, Medical University of ViennaType of Session: PlenaryBackground In treating early-stage breast cancers with favorable prognostic features, the question has been...
Patterns of Locoregional Recurrence and Their Predictors in Rectal Cancer Patients Treated with Surgery and Chemoradiation Presenter: T. Yu.Presenter's Affiliation: MD Andersen Cancer CenterType of Session: ScientificBackground The current standard of care for treating locally advanced rectal cancer is combined modality chemotherapy and radiation with surgical...
Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794) Presenter: G. P. SwansonPresenter's Affiliation: UT San AntonioType of Session: PlenaryBackground Prostate cancer patients with adverse findings at surgery have an increased risk of local failure. Although radiation in the post-prostatectomy...
Preliminary Analysis of Cancer and Leukemia Group B (CALGB) 80003: A Phase II trial of Gemcitabine, 5-Fluorouracil (5FU) and Radiation Therapy (RT) in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma. Presenter: Harvey MamonPresenter's Affiliation: Dana Farber/Brigham and Women's Cancer Center, Boston, MAType of Session: ScientificBackground The median survival for locally advanced, unresectable pancreatic cancer is quite low after...
Preoperative Chemo-radiotherapy (CT-RT) Improves Local Control in T3-T4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial Presenter: P. RomestaingPresenter's Affiliation: CHU Lyon Sud, Lyon, FranceType of Session: PlenaryBackground Based on prior studies on the role of chemo-radiation in the management of patients with locally advanced rectal cancers (LARC), there has...
Radiation Therapy (RT) as a Chemosensitizer of Gemcitabine (G) in Patients with Metastatic/Unresectable Tumors of the Gastrointestinal (GI) Tract - a Phase I/II Study Exploring a New Treatment Paradigm Presenter: W. F. Regine, MDPresenter's Affiliation: University of Maryland, Baltimore, MDType of Session: ScientificBackground Gemcitabine is one of the most active chemotherapy drugs for the treatment of metastatic/unresectable pancreatic...
Surveillance Should Be the Standard Approach in Patients with Stage I Seminoma Presenter: P. R. WardePresenter's Affiliation: Princess Margaret Hospital, Toronto, ONType of Session: ScientificBackground Management options for stage I seminoma in the adjuvant setting include radiotherapy, chemotherapy, and surveillance. Although...
The Prognostic Value of the Epidermal Growth Factor Receptor in Locally Advanced Rectal Cancer (LARC) Patients Treated with Preoperative Chemo-radiation Presenter: J. KimPresenter's Affiliation: Radiation Oncology, Chungnam National University, College of Medicine, Daejon, South KoreaType of Session: ScientificBackground More recently, the use of targeted agents against epidermal growth factor...